Medesis Pharma S.A. (ALMDP.PA)
Medesis Pharma S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Montpellier, FR. The stock last traded at $0.35, up 0.00% on the session, giving a market capitalisation of $1.8M. Its beta of 0.18 implies it has historically moved less than the broad market.
Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to creating orally delivered molecular drug therapies aimed at critical medical conditions lacking effective treatments. The company's pipeline features several innovative compounds, including NanoLithium (NP03), which is currently undergoing clinical trials for Alzheimer's disease, and NanosiRNA DH, targeting Huntington's Disease. Medesis Pharma also develops NU01 Plutonium and NU02 Cesium for nuclear decorporation, alongside NP02 – NanoManganese, a radioprotection medication designed for individuals exposed to radiation from nuclear incidents. Furthermore, their portfolio encompasses NanosiRNA COVID-19, an antiviral solution for various viral infections, and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for oncological applications. Established in 2003, the enterprise operates from its headquarters in Montpellier, France.
Medesis Pharma S.A. is most often compared with the following Healthcare names: